Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China. https://doi.org/10.1002/jmv.26193 In this descriptive observational study, we aimed to discuss the treatment response of HCQ in COVID-19 infected patients and 30 cases… Continue reading "(12 Aug 2020) Hydroxychloroquine- Early use better than later use"
Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin – A real world experience https://doi.org/10.1101/2020.08.05.20151027 This is a retrospective observational study to assess the effect of HCQ and Azithromycin on duration from symptom onset to… Continue reading "(11 Aug 2020) Hydroxychloroquine and Azithromycin-delayed SARS-CoV-2 virus clearance"
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature https://doi.org/10.1101/2020.08.05.20169060 A retrospective study of patients admitted to the University of Washington Hospital system with COVID-19 and requiring supplemental oxygen was conducted.… Continue reading "(11 Aug 2020) Tocilizumab- associated with reduced CRP, fibrinogen, and temperature"
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study https://doi.org/10.1002/jmv.26407 This was a retrospective intent-to-treat analysis of the hospitalized patients who started LPV/r+HCQ between 21 February and 20 March 2020.… Continue reading "(11 Aug 2020) Lopinavir/R and Hydroxychoroquine- several adverse events and no effect on clinical course"
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results https://doi.org/10.1016/j.ijantimicag.2020.106136 A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to our ICU with a confirmed… Continue reading "(11 Aug 2020) Hydroxychloroquine- administration in critically ill patients not useful"
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort https://doi.org/10.1007/s00508-020-01720-y Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20… Continue reading "(11 Aug 2020) Hydroxychloroquine, Lopinavir/R- No statistically significant differences with HCQ or LPV/RTV"
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1093/cid/ciaa1176 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(10 Aug 2020) Favipiravir-viral clearance in 62.5% of patients within 4 days"
Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab https://www.ijidonline.com/article/S1201-9712(20)30609-3/fulltext In a retrospective cohort study, at tocilizumab initiation (n = 52), 50 (96.2%) were intubated, and only 7 (13.5%) received concomitant corticosteroids. At anakinra initiation (n =… Continue reading "(10 Aug 2020) Tocilizumab, Anakinra- Prompt identification and treatment of COVID19-CS prior to intubation important"
Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation https://doi.org/10.1016/j.ijid.2020.07.078 Ten consecutive patients (6 males, median age 55 years) treated with TCZ on top of SOC, and ten patients (6 males, median age… Continue reading "(10 Aug 2020) Tocilizumab-TCZ-treated patients show no disease progression"
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2016638 In this randomized, double-blind, placebo-controlled trial (NCT04308668. opens in new tab), the efficacy of hydroxychloroquine as Covid-19 postexposure prophylaxis was investigated. In this trial, high doses of hydroxychloroquine did… Continue reading "(06 Aug 2020) Hydroxychloroquine- did not prevent illness compatible with Covid-19"
